MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Intellia Therapeutics Depreciation & Amortization 2011-2026 | NTLA
Annual Depreciation & Amortization Intellia Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.3 M | 8.98 M | 7.57 M | 6.89 M | 6.31 M | 5.59 M | 4.46 M | 2.99 M | 1.1 M | 328 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.3 M | 328 K | 5.45 M |
Quarterly Depreciation & Amortization Intellia Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.4 M | 2.5 M | 2.5 M | - | 2.6 M | 2.6 M | 2.51 M | - | - | - | 2.05 M | - | 5.54 M | - | 1.75 M | - | 5.01 M | - | 1.59 M | - | 4.71 M | 3.11 M | 1.54 M | - | 4.02 M | 2.64 M | 1.3 M | - | 3.24 M | 2.08 M | 1.01 M | - | 2.16 M | 1.37 M | 660 K | - | 699 K | 434 K | 187 K | - | 196 K | 100 K | 33 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.54 M | 33 K | 2.09 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aytu BioScience
AYTU
|
5.38 M | $ 2.66 | - | $ 16.7 M |  USA |
 |
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M |  China |
 |
Cerus Corporation
CERS
|
1.43 M | $ 1.85 | - | $ 353 M | USA |
 |
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | USA |
 |
Coherus BioSciences
CHRS
|
1.3 M | $ 1.67 | - | $ 196 M | USA |
 |
Celldex Therapeutics
CLDX
|
3.38 M | $ 31.37 | - | $ 2.08 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
1.04 M | $ 0.44 | - | $ 5.04 M |  Israel |
 |
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
3.92 K | $ 2.32 | - | $ 1.03 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
375 K | $ 24.98 | - | $ 3.05 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
233 K | $ 10.14 | - | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
364 K | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
169 K | $ 0.53 | - | $ 6.98 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
3.9 M | $ 37.7 | - | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
19.5 M | $ 49.15 | - | $ 4.42 B |  Schweiz |
 |
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | USA |
 |
CytomX Therapeutics
CTMX
|
1.2 M | $ 4.4 | - | $ 607 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
1.43 K | $ 0.86 | - | $ 5.79 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | USA |
 |
Cue Biopharma
CUE
|
958 K | $ 0.18 | - | $ 17.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.99 M | $ 20.36 | - | $ 2.84 B |  France |
 |
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | Canada |
 |
Denali Therapeutics
DNLI
|
7.8 M | $ 19.38 | - | $ 3.19 B | USA |
 |
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | USA |
 |
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.54 | - | $ 238 B |  Britain |
 |
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | USA |
 |
Equillium
EQ
|
116 K | $ 2.01 | - | $ 115 M | USA |
 |
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 330.34 | - | $ 43.3 B | USA |
 |
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | USA |
 |
Fate Therapeutics
FATE
|
12.9 M | $ 1.19 | - | $ 141 M | USA |
 |
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | USA |